Citius pharmaceuticals enrolls first patient in phase 2b study of halo-lido for the prescription treatment of hemorrhoids

Primary endpoint is the reduction in hemorrhoidal symptoms cranford, n.j. , april 26, 2022 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the first patient has been enrolled in the company's phase 2b clinical study of halo-lido for the treatment of hemorrhoids.
CTXR Ratings Summary
CTXR Quant Ranking